Immunoallergy Laboratory, Immunology Department, Instituto de Investigación Sanitaria Fundación Jiménez Díaz (IIS-FJD), Madrid, Spain.
CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain.
Front Immunol. 2021 Jan 8;11:608666. doi: 10.3389/fimmu.2020.608666. eCollection 2020.
Chronic respiratory diseases (CRDs) are an important factor of morbidity and mortality, accounting for approximately 6% of total deaths worldwide. The main CRDs are asthma and chronic obstructive pulmonary disease (COPD). These complex diseases have different triggers including allergens, pollutants, tobacco smoke, and other risk factors. It is important to highlight that although CRDs are incurable, various forms of treatment improve shortness of breath and quality of life. The search for tools that can ensure accurate diagnosis and treatment is crucial. MicroRNAs (miRNAs) are small non-coding RNAs and have been described as promising diagnostic and therapeutic biomarkers for CRDs. They are implicated in multiple processes of asthma and COPD, regulating pathways associated with inflammation, thereby showing that miRNAs are critical regulators of the immune response. Indeed, miRNAs have been found to be deregulated in several biofluids (sputum, bronchoalveolar lavage, and serum) and in both structural lung and immune cells of patients in comparison to healthy subjects, showing their potential role as biomarkers. Also, miRNAs play a part in the development or termination of histopathological changes and comorbidities, revealing the complexity of miRNA regulation and opening up new treatment possibilities. Finally, miRNAs have been proposed as prognostic tools in response to both conventional and biologic treatments for asthma or COPD, and miRNA-based treatment has emerged as a potential approach for clinical intervention in these respiratory diseases; however, this field is still in development. The present review applies a systems biology approach to the understanding of miRNA regulatory networks in asthma and COPD, summarizing their roles in pathophysiology, diagnosis, and treatment.
慢性呼吸系统疾病(CRD)是发病率和死亡率的一个重要因素,约占全球总死亡人数的 6%。主要的 CRD 包括哮喘和慢性阻塞性肺疾病(COPD)。这些复杂的疾病有不同的诱因,包括过敏原、污染物、烟草烟雾和其他危险因素。重要的是要强调,尽管 CRD 是不可治愈的,但各种形式的治疗可以改善呼吸困难和生活质量。寻找可以确保准确诊断和治疗的工具是至关重要的。微小 RNA(miRNA)是小的非编码 RNA,已被描述为 CRD 的有前途的诊断和治疗生物标志物。它们参与哮喘和 COPD 的多个过程,调节与炎症相关的途径,表明 miRNA 是免疫反应的关键调节剂。事实上,已经在几种生物流体(痰、支气管肺泡灌洗液和血清)以及与健康受试者相比的患者的结构性肺和免疫细胞中发现 miRNA 失调,表明它们作为生物标志物的潜在作用。此外,miRNA 在组织病理学变化和合并症的发展或终止中起作用,揭示了 miRNA 调节的复杂性,并为新的治疗可能性开辟了道路。最后,miRNA 已被提议作为哮喘或 COPD 对常规和生物治疗的反应的预后工具,并且基于 miRNA 的治疗已成为这些呼吸系统疾病临床干预的潜在方法;然而,这一领域仍在发展中。本综述应用系统生物学方法来理解哮喘和 COPD 中 miRNA 调节网络,总结它们在病理生理学、诊断和治疗中的作用。